Impax Asset Management Group
HZNP

Impax Asset Management Group’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Impax Asset Management Group’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-200,000
Closed -$5.92M – 294
2020
Q1 		$5.92M Buy
200,000
+130,000
+186% +$4.4M 0.08% 137
2019
Q4 		$2.53M Buy
+70,000
New +$2.15M 0.03% 189

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Impax Asset Management Group's HZNP Position: Q2 2020 in Review

Impax Asset Management Group sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2020, closing a stake of 200,000 shares — an estimated $5.92M sold.

Impax Asset Management Group first reported a position in HZNP in Q4 2019 and held it in 2 quarters. The position peaked at $5.92M in Q1 2020. 354 funds tracked by Wall St. Rank hold HZNP as of Q2 2020.

  • Impax Asset Management Group reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2020 after selling out during the quarter.
  • Impax Asset Management Group sold 200,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2020, an estimated $5.92M.
  • Impax Asset Management Group first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2019 and held it in 2 quarters.
  • Impax Asset Management Group's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.92M in Q1 2020.
  • 354 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2020.

Based on Impax Asset Management Group's 13F filing for Q2 2020, filed 14 Aug 2020.